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Background: The present study was aimed at determining the prophylactic efficacy of American cranberry (AC)
extract (Cysticlean®) in women with recurrent symptomatic postcoital urinary tract infections (PCUTI), non-consumer
of AC extract in the past 3 months before inclusion, and to determine changes in their quality of life (QoL).
Methods: This was a single center, observational, prospective study in a total of 20 women (mean age 35.2 years;
50.0% were married). Patients were followed up for 3 and 6 months during treatment.
Results: The number of PCUTIs in the previous 3 months prior to start the treatment with Cysticlean® was 2.8±1.3
and it was reduced to 0.2±0.5 at Month 6 (P<0.0001), which represent a 93% improvement. At baseline, the mean
score on the VAS scale (range from 0 to 100) for assessing the QoL was 62.4±19.1, increasing to 78.2±12.4 at Month
6 (P=0.0002), which represents a 20% improvement. All patients had an infection with positive urine culture at
baseline, after 6 months there were only 3 symptomatic infections (P<0.001). The most common bacterium was
Escherichia coli.
Conclusions: Prophylaxis with American cranberry extract (Cysticlean®) could be an alternative to classical therapies
with antibiotics. Further studies are needed to confirm results obtained in this pilot study.
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The high prevalence of urinary tract infections (UTIs)
causes a major social and health impact. 37% of women
suffer at least one episode of cystitis during their life-
time, of these, 20% recur in the first two months due to
poor cure of infection, resistance to antibiotics or poor
hygiene habits. In addition, 12% have recurrent cystitis,
that is, they suffer more than 2 episodes of cystitis in a
year [1].
Cystitis affects predominantly women aged between 20
and 60 years. The most common causes include: alter-
ation of the vaginal flora, cold and humidity, low inser-
tion of the urethral meatus, chronic constipation, lack of* Correspondence: sanchezballester@gmail.com
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distribution, and reproduction in any mediumlubrication and frequency of sexual intercourse, urinary
retention and misuse of antibiotics.
To deal with this situation, different therapeutic op-
tions have been proposed. After establishing a presump-
tive diagnosis of UTI, antibiotic therapy is instituted
until the result of the antibiotic susceptibility testing of
the urinary culture is obtained. When infections are
recurrent, the possibility of administering antibiotic
prophylaxis temporarily can be considered, though given
the gradual increase in the number of antibiotic resis-
tances of the most common pathogens, the current
trend is to search for other options [2].
Cysticlean® (Vaccinium macrocarpon) (hereinafter
named Cys) is a dietary food supplement based on
concentrated American cranberry (AC) extract. AC is
known for its antibacterial properties and benefits on
health of the urinary tract due to its high content in
proantocyanidins (PAC) and, to a lesser extent, quinicd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Pharmacopeia) to measure PAC contents on AC, and
this is the reason AC preparations with similar PAC con-
tent do not have the same antiadhesive effect against
Escherichia coli. Cys is the AC extract marketed in Spain
with greater antiadhesive capacity against E. coli (83%
and 76% in the sachet and capsule forms, respectively),
the main cause of UTIs [4].
The use of concentrated AC extract has no reported
contraindications or side effects. It is thus ideal as a
long-term treatment to prevent cystitis recurrences. Very
rare cases of interaction with warfarin have been
reported, but all were associated with massive intake of
AC juice for several days [2].
Based on the above, this pilot study was conducted to
determine the prophylactic efficacy of AC extract (Cys)
in women with recurrent symptomatic postcoital urinary
tract infections (PCUTIs) and its impact on their quality
of life.
Methods
Study design and patient selection
This was a single center, observational, prospective study
conducted in an Urodynamics Unit (Voiding Function
Unit) in Voiding Functional Unit, Hospital Quiron,
Valencia, Spain from August 2011 to June 2012. We
consider PCUTI when the symptoms appeared up to
48 hours after sexual intercourse [5,6]. The study in-
cluded women aged 18 to 60 years old, with at least two
PCUTIs due to E. coli in the past year and with active
infection confirmed by symptomatic positive urine cul-
ture to E. coli at the beginning of the study. After treat-
ment with antibiotics a culture was taken to confirm the
absence of infection. Patients were counseled in previous
visits about vaginal hygiene measures, particularly
avoiding use of spermicidal creams and oral contracep-
tives. Patients with regular consumption of Cys withinFigure 1 Flow diagram.the past three months, a bladder neoplasm, urinary
stones, postvoid residual urine > 100 cc, or obstructive
urinary symptoms were excluded from the study.
Patients included received Cys (PACs 118 mg/day) for
6 months as follows: after 1st sexual intercourse in a week
received 1 Cys sachet daily for 3 days, and after 2nd and
following intercourses in a week received only 1 Cys
sachet postcoital (Figure 1).
The primary objective of the study was to determine
the prophylactic efficacy of AC extract in women with
PCUTIs. The secondary objectives were to determine
the tolerability of Cys, and to determine changes in QoL
of patients with PCUTIs taking Cys.
The study was carried out according to the European
Guidelines for Good Epidemiological Practice [7], and
the provision of the Declaration of Helsinki (as revised
in Tokyo 2008). The study was approved by the Clinical
Research Ethics Committee of the University of Valencia,
and followed the Spanish Law 15/1999 on Personal
Character Data Protection concerning confidentiality of
patients’ data. All patients participating in the study signed
the corresponding written consent form.
Study variables
The total length of the study was 6 months per patient,
including 3 visits (Baseline, Month 3 and Month 6). The
following patient data were collected using a Case Rec-
ord Form specifically designed for this study: socio-
demographic data, concomitant diseases, microbiological
data, characteristics of PCUTIs, voiding habits, vaginal
hygiene, QoL, patient status in the study and adverse
events.
Urine culture was carried out for patients presenting
at least one symptom of infection and if the result was
positive they were administered antibiotic treatment. In
this way microbiological data were only obtained in
presence of PCUTIs after treatment with Cys.
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of patients including sexual relations by using a Visual
Analogue Scale (VAS), ranging 0–100 mm, where 0 is
the worst imaginable health state and 100 the best
imaginable health state.
Statistical analyses
Descriptive statistics were performed for all variables an-
alyzed. Measures of central tendency and dispersion with
their 95% confidence interval are shown for quantitative
variables, while absolute and relative frequencies are
shown for qualitative variables.
The distribution type of the continuous variables was
studied and its adjustment to the Gaussian distribution
was assessed using the Kolmogorov-Smirnov test. The
statistical significance of the changes from baseline at
Month 3 and Month 6 (analysis of the paired data) was
obtained using Student’s t-test for quantitative variables,
the McNemar test for dichotomous qualitative variables,
and the McNemar-Bowker test for ordinal qualitative
variables. P-values were based on two-sided testing at a
5% significance level. All data were analyzed using SAS
statistical package version 9.0.
Results
Sociodemographic data and concomitant diseases
The mean age of the 20 patients included in the study
was 35.2 (± 9.6) years, all had been schooled and 50.0%
were married. Only 5 patients had concomitant diseases:
2 (10.0%) had dyslipemia, 1 (5.0%) had multiple sclerosis,
1 (5.0%) had hypertension and 1 (5.0%) had allergic
rhinitis.
Clinical data
The mean number of PCUTIs over the previous
3 months at baseline (prior to start treatment with Cys)
significantly decreased from 2.8 (± 1.3) at baseline to 0.7
(± 1.0) at Month 3 (P<0.0001) and continued decreasing
to 0.2 (± 0.5) at Month 6 (P<0.0001). Table 1 shows the
percentage of patients with PCUTIs.
At inclusion, patients reported that they had presented




Month 3 Month 6
(n=20) (n=20) (n=20)
Percentage of patients with
PCUTIs (previous 3 months)
20 (100%) 10 (50 %) 3 (15 %)
P-value vs. Baseline 0.0016* <0.0001*
P-value month 6 vs. Month 3 0.0082*
* statistically significant.Voiding habits
Concerning voiding habits over the previous 3 months,
at baseline 40.0% of patients reported urinating before
intercourse and 65.0% reported urinating after inter-
course, and after 3 months these percentages increased
to 50.0% and 75.0%, respectively, being maintained after
6 months. 40.0% of patients reported being regular
urinators at baseline as well as at Month 6. No statisti-
cally significant differences were found in any case,
except for tendency to retain urine reported by 25.0% of
patients at baseline and significantly decreasing (P<0.05)
to 5.0% both at Month 3 and at Month 6.
Vaginal hygiene
There were no changes in vaginal hygiene from baseline
visit during the study. 70.0% of patients practiced normal
vaginal hygiene (once daily with daily bath, without use
of antiseptic substances or special soaps), 25.0% prac-
ticed moderate hygiene (once or twice daily, postcoital
or after urinating), and 5.0% practiced extreme hygiene
(several times a day and even with vaginal antiseptic).
Partners, spermicidal creams and oral contraceptives
Patients did not report change in the kind and frequency
of intercourse, maintained the same partner and
reported no changes in use of spermicidal creams and
oral contraceptives.
QoL (VAS)
The mean change from baseline on the VAS scale (range
from 0 to 100) was 8.7 (±13.7) at Month 3 and 15.8
(± 15.5) at Month 6. Both changes were statistically
significant (P=0.0110 and P=0.0002, respectively).
Figure 2 shows the mean score per visit with the
corresponding 95% confidence intervals.
Presence of bacteria causing PCUTIs
As per the inclusion criteria, at baseline all 20 patients
had an infection with positive urine culture to the pres-
ence of bacteria causing PCUTIs (Table 1).
The most common bacteria causing PCUTIs was
E. coli, being present in all 20 patients at baseline and
significantly decreasing its presence to 6 patients after
3 months (P=0.0002) and to only 2 patients after 6 months
(P<0.0001).
Adverse events
No adverse events occurred during the study and no
patient had side effects derived from taking AC extract.
Discussion and conclusion
As far as we know this is the first study conducted to
directly assess the potential benefit of AC extracts in the
prevention of PCUTIs. Recently published reviews on
Figure 2 Quality of life (VAS). Results are expressed as mean (± SD) with the corresponding 95% confidence intervals.
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AC products, but none specifically address postcoital
UTI [8-11]. In a systematic review of literature carried
out on the use of AC in chronic urinary infections, no
studies on postcoital use of AC were found [12].
AC is a widely used and recommended remedy for
prophylaxis of UTI and several clinical trials have docu-
mented its efficacy in women with recurrent UTI
[4,13,14]. AC contains type A proanthocyanidin (PAC)
that inhibits adherence, in doing so preventing the
colonization of the E. coli uropathogen in the vaginal
mucosa and reducing the frequency of bacteriuria, and
this effect occurs in a dose dependent manner [15-19].
According to a recent updated Cochrane review [20],
AC juice does not appear to have a significant benefit in
preventing UTI, even though on a prior update it
appeared that there was some evidence that AC juice
may decrease the number of symptomatic UTIs over a
12 month period, particularly for women with recurrent
UTIs [21]. However, the update recommended more
studies to evaluate AC products such as tablets or cap-
sules on women with recurrent UTIs (20). In a random-
ized controlled trial in elderly women to compare the
efficacy in preventing UTI of AC capsules versus
trimethoprim in preventing UTI, there were no signifi-
cantly differences between groups concerning time to
first recurrence of UTI, and trimethoprim had a very
limited advantage over AC in the prevention of recur-
rent UTI in older women, but had more adverse effects
and withdrawals [22]. In the elderly population there
was only one clinical trial with asymptomatic bacteriuria,
which showed that bacteriuria and pyuria were signifi-
cantly reduced in women taking AC juice in comparison
with women who received placebo [23]. Several meta-
analyses have established that recurrence rates over
1 year are reduced approximately 35% in young to
middle-aged women [24].The results of the present study confirmed the efficacy
of Cys as previously described, with a significant de-
crease of 75% in the number of PCUTIs after 3 months
of Cys intake, until 93% after 6 months. Although the
composition of effective AC products and its dosage in
UTI prophylaxis have not yet been defined, 13 it has
been demonstrated that AC extract containing higher
doses of PACs produce a greater benefit [25] and a dose
of 118 mg/day of PACs has demonstrated a significant
efficacy in different clinical trials with Cys [26].
The current management of recurrent UTI involves
repeated courses of antibiotics or subtherapeutic,
long-term antibiotic prophylaxis [27]. However, adverse
effects are common with these treatments, as well as
increasing antibiotic resistance [28]. The increasing preva-
lence of E. coli isolates (the most common uropathogen)
that are resistant to antimicrobial agents, together with
the high costs of antibiotic treatments, have stimulated
interest in novel non-antibiotic methods for the preven-
tion of UTI [25]. Given the reduction of the number of
antibiotic treatments per patient with the use of Cys, as
demonstrated by the results of the present study, this
should theoretically decrease occurrence of microbial
resistance.
Prevention of recurrent UTIs includes early postcoital
voiding habits [29,30]. In fact, the American College of
Obstetricians and Gynecologists District II NYS recom-
mends urinating after sexual intercourse to prevent re-
current cystitis. Nevertheless, there is no proven
association between recurrent UTIs and pre or
postcoital voiding patterns, frequency of urination, wip-
ing patterns, douching, use of tight undergarments, or
delayed voiding habits [31,32]. The results from the
present study showed increasing urinating habits before
and after sexual intercourse of approximately 20%
already after 3 months of AC extract daily intake. Fur-
thermore, as there were no changes in vaginal hygiene
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mainly attributable to Cys daily intake.
One issue for discussion is the pattern of treatment to
be administered. We decided a treatment of 3 days
simulating the guidelines of antibiotic treatment in
PCUTI [33]. However, based on the dose dependent
effect of PAC and previous experience with antibiotic
profilaxis in PCUTI, we suspect that the administration
of higher doses in a shorter interval of time should be
equally effective.
Urinary tract infections have an detrimental impact on
patients QoL [34,35]. Although uncomplicated UTI in
women is considered to be a relatively benign and
self-limiting condition, it is responsible for significant
symptomatology, morbidity and loss of QoL and causes
unnecessary suffering, affecting patient’s daily activities,
social functioning and wellbeing, and sexual intercourse
which, is not satisfactory [36]. Consequently, a decrease of
recurrent symptomatic infections should relate to an
increase of QoL. In the present study we use a VAS score
to assess QoL. Although not a standardized method for
assessing QoL, we selected it for its simple completion
and interpretation. There was a significant increase of 20%
in the QoL evaluation related to the decrease found in the
mean number of PCUTIs in which patients had taken
antibiotics after 6 months of Cys daily intake.
Finally, in the present study there was a significant
reduction of patients with symptomatic infections after
3 months and again after 6 months. It should be taken
into account that urine cultures were only carried out
in presence of PCUTIs, therefore the high percentage
of women with culture not done should be considered as
a treatment success. Thus Cys improves QoL decreasing
infections derived from sexual intercourse. Further studies
are needed to confirm results obtained in this pilot study.
The use of AC products appears to be safe. The
present study confirmed the safe profile of Cys as there
were no adverse events at all. Prophylaxis of Cys seems
to be a promising option to decrease the number of
PCUTIs and therefore increase QoL.
The results of this pilot study are not significant due
to the short follow-up period and the limited number of
patients. We believe is needed a randomized placebo
controlled study with at least 50 patients and follow up
should be one year. However, over longer periods of time
changes in sexual habits, contraception methods, or regu-
lar partner can occur, which may invalidate the study.
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